Nonlinearity of the Inverse Relationship between High-Density Lipoprotein (HDL) Cholesterol and Incident Cardiovascular Risk: Is It Time to Revisit the “HDL Hypothesis”?
Hashem C, Altin S, Guyton J, Boden W. Nonlinearity of the Inverse Relationship between High-Density Lipoprotein (HDL) Cholesterol and Incident Cardiovascular Risk: Is It Time to Revisit the “HDL Hypothesis”? Journal Of Clinical Lipidology 2024 PMID: 39934033, DOI: 10.1016/j.jacl.2024.12.009.Peer-Reviewed Original ResearchLow HDL-CHDL-C levelsHDL-CAssociated with atherosclerotic cardiovascular diseaseRandomized controlled trialsLow levels of high-density lipoprotein cholesterolLow HDL-C levelsLevels of high-density lipoprotein cholesterolIncident cardiovascular riskLevels of HDL-CReduce ASCVD eventsHigh-density lipoprotein cholesterolOptimal risk stratificationHigh-density lipoprotein (HDLStatin-based therapyHDL hypothesisAtherosclerotic cardiovascular diseaseLipoprotein (HDLRisk-enhancing factorsIncident cardiovascular eventsCholesterol guidelinesRisk stratificationCardiovascular eventsLipoprotein cholesterolCardiovascular riskEndovascular versus surgical revascularization for patients with chronic limb‐threatening ischemia: A systematic review and meta‐analysis of randomized controlled trials
Balakrishna A, Alla V, Aronow H, Secemsky E, Altin S, Jayasuriya S, Goldsweig A. Endovascular versus surgical revascularization for patients with chronic limb‐threatening ischemia: A systematic review and meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2024, 104: 1012-1014. PMID: 39162243, DOI: 10.1002/ccd.31200.Peer-Reviewed Original ResearchF-12 | Endovascular versus surgical revascularization for patients with chronic limb threatening ischemia: A systematic review and meta-analysis of randomized controlled trials
Balakrishna A, Alla V, Aronow H, Secemsky E, Altin S, Jayasuriya S, Goldsweig A. F-12 | Endovascular versus surgical revascularization for patients with chronic limb threatening ischemia: A systematic review and meta-analysis of randomized controlled trials. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101821. DOI: 10.1016/j.jscai.2024.101821.Peer-Reviewed Original ResearchDuration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply